Erythropoietin and preoperative autologous blood donation in the prevention of hepatitis C infection: Necessity or luxury?

Transfusion

Volumn 39, Issue 9, 1999, Pages 933-937

  Woronoff Lemsi, Marie Christine ^a,b   Arveux, P ^a   Limat, S ^a   Morel, P ^a   Le Pen, C ^a   Cahn, J Y ^a  

^a UNIVERSITÉ PARIS DAUPHINE   (France)

^b UNIVERSITY HOSPITAL OF BESANÇON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ARTICLE; BLOOD AUTOTRANSFUSION; BLOOD DONOR; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DECISION THEORY; DRUG EFFICACY; ERYTHROCYTE TRANSFUSION; FRANCE; HEPATITIS C; INFECTION RISK; PREOPERATIVE TREATMENT; TOTAL HIP PROSTHESIS; VIRUS TRANSMISSION;

BLOOD DONORS; BLOOD TRANSFUSION, AUTOLOGOUS; COMBINED MODALITY THERAPY; COST-BENEFIT ANALYSIS; ERYTHROPOIETIN, RECOMBINANT; HEPATITIS C; HUMANS; PREOPERATIVE CARE; SENSITIVITY AND SPECIFICITY;

EID: 0032823827     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1537-2995.1999.39090933.x     Document Type: Article

References (12)

1. Morel P, Herve P. Surveillance of blood transfusion safety: contribution of the hemovigilance strategy in France. Transfus Med Rev 1998;12:109-27.
2. Lorentz A, Eckardt KU, Osswald PM, Duchow JR. Erythropoietin levels in patients depositing autologous blood in short intervals. Ann Hematol 1992;64:281-5.
3. Etchason J, Petz L, Keeler E, et al. The cost effectiveness of preoperative autologous blood donations. N Engl J Med 1995;332:719-24.
4. NIH consensus conference targets prevention and management of hepatitis C. Am Fam Physician 1997;56:959-61.
5. Bennett WG, Inoue Y, Beck JR, et al. Estimates of the cost-effectiveness of a single course of interferon-α2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997;127:855-65.
6. Kim WR, Poterucha JJ, Hermans JE, et al. Cost-effectiveness of 6 and 12 months of interferon-α therapy for chronic hepatitis C. Ann Intern Med 1997;127:866-74.
7. Biesma DH, Marx JJ, Kraaijenhagen RJ, et al. Lower homologous blood requirement in autologous blood donors after treatment with recombinant human erythropoietin. Lancet 1994;344:367-70.
8. Menitove JE. Transfusion-transmitted infections: update. Semin Hematol 1996;33:290-301.
9. [Official tariff for blood components: decree of 29 March 1996.] Official Journal of the French Republic April 3, 1996:5130-1.
10. De Andrade JR, Jove M, Landon G, et al. Baseline hemoglobin as a predictor of risk of transfusion and response to Epoetin alfa in orthopedic surgery patients. Am J Orthop 1996;25:533-42.
11. Donahue JG, Munoz A, Ness PM, et al. The declining risk of post-transfusion hepatitis C virus infection. N Engl J Med 1992;327:369-73.
12. Mercuriali F, Zanella A, Barosi G, et al. Use of erythropoietin to increase the volume of autologous blood donated by orthopedic patients. Transfusion 1993;33:55-60.